Ascendis Pharma A/S (NASDAQ:ASND) is Avoro Capital Advisors LLC’s 3rd Largest Position

Avoro Capital Advisors LLC raised its stake in shares of Ascendis Pharma A/S (NASDAQ:ASND) by 5.8% in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 4,196,661 shares of the biotechnology company’s stock after buying an additional 229,995 shares during the period. Ascendis Pharma A/S comprises about 7.6% of Avoro Capital Advisors LLC’s investment portfolio, making the stock its 3rd biggest holding. Avoro Capital Advisors LLC owned 7.21% of Ascendis Pharma A/S worth $572,341,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also modified their holdings of ASND. Private Ocean LLC acquired a new position in Ascendis Pharma A/S in the first quarter worth approximately $36,000. Quadrant Capital Group LLC raised its holdings in shares of Ascendis Pharma A/S by 90.4% during the 4th quarter. Quadrant Capital Group LLC now owns 318 shares of the biotechnology company’s stock valued at $40,000 after purchasing an additional 151 shares in the last quarter. EverSource Wealth Advisors LLC raised its holdings in shares of Ascendis Pharma A/S by 37.6% during the 4th quarter. EverSource Wealth Advisors LLC now owns 333 shares of the biotechnology company’s stock valued at $42,000 after purchasing an additional 91 shares in the last quarter. GAMMA Investing LLC boosted its holdings in Ascendis Pharma A/S by 52.0% in the first quarter. GAMMA Investing LLC now owns 298 shares of the biotechnology company’s stock worth $45,000 after purchasing an additional 102 shares in the last quarter. Finally, Barometer Capital Management Inc. bought a new stake in Ascendis Pharma A/S in the fourth quarter worth $126,000.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on ASND. Bank of America boosted their price target on Ascendis Pharma A/S from $165.00 to $175.00 and gave the stock a “buy” rating in a research report on Wednesday, September 4th. Evercore ISI boosted their target price on Ascendis Pharma A/S from $191.00 to $205.00 and gave the stock an “outperform” rating in a report on Tuesday, September 17th. The Goldman Sachs Group upped their target price on Ascendis Pharma A/S from $180.00 to $200.00 and gave the stock a “buy” rating in a research report on Tuesday, September 17th. Oppenheimer reissued an “outperform” rating and issued a $190.00 price target (up previously from $180.00) on shares of Ascendis Pharma A/S in a research report on Tuesday, September 17th. Finally, Citigroup upped their price objective on shares of Ascendis Pharma A/S from $178.00 to $207.00 and gave the stock a “buy” rating in a report on Tuesday, September 17th. Two investment analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $193.77.

Ascendis Pharma A/S Stock Performance

NASDAQ ASND opened at $151.26 on Monday. Ascendis Pharma A/S has a twelve month low of $85.29 and a twelve month high of $161.00. The stock has a market cap of $8.81 billion, a PE ratio of -15.74 and a beta of 0.63. The firm has a 50-day simple moving average of $133.56 and a 200 day simple moving average of $136.50.

Ascendis Pharma A/S Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.